Please login to the form below

Not currently logged in
Email:
Password:

Opioid analgesic

This page shows the latest Opioid analgesic news and features for those working in and with pharma, biotech and healthcare.

FDA committee rejects Intellipharmaceutics’ opioid drug Aximris

FDA committee rejects Intellipharmaceutics’ opioid drug Aximris

Verdict closely follows rejection of Nektar’s opioid analgesic. The FDA’s Anesthetic and Analgesic Committee has rejected yet another opioid drug – this time Intellipharmaceutics’ extended-release oxycodone tablet Aximiris. . ... Despite finding

Latest news

  • Nektar’s opioid analgesic slammed with FDA panel rejection Nektar’s opioid analgesic slammed with FDA panel rejection

    High levels of euphoric side-effects from opioid medications have lead to abuse and addiction, which has caused a healthcare crisis to erupt across the US. ... Although the rejection is a blow to Nektar, the opioid painkiller had already been somewhat

  • Insys gets bankruptcy court okay for Subsys sale Insys gets bankruptcy court okay for Subsys sale

    Opioid product was focus of racketeering charges. Insys Therapeutics has been given the green light to sell its Subsys opioid product – the focus of racketeering charges that forced the company to ... Subsys is a sublingual spray formulation of fentanyl

  • Nektar confirms BMS deal for NKTR-214 is on track Nektar confirms BMS deal for NKTR-214 is on track

    Almost forgotten among the interest in Nektar’s immuno-oncology pipeline – which also includes three other candidates in clinical trials – is NKTR-181, a first-in-class, abuse-deterrent opioid analgesic ... The drug promises to deliver pain relief

  • Endo faces industry-first FDA call to pull its opioid painkiller Endo faces industry-first FDA call to pull its opioid painkiller

    The painkiller was first approved in 2006 to manage moderate-to-sever pain when a continuous, around-the-clock opioid analgesic was needed for an extended period of time, but an ... abuse.”. Opioid overdoses killed 33, 000 Americans in 2015 - with half

  • Purdue gets FDA nod for abuse-deterrent painkiller Purdue gets FDA nod for abuse-deterrent painkiller

    Purdue Pharma has expanded its portfolio of opioid analgesic drugs following FDA approval of Hysingla ER, a once-daily product designed to resist abuse. ... The new product will compete in the marketplace against products such as Zogenix' 12-hour Zohydro

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
Guide
How to embrace behavioural science principles in healthcare MR...